Abstract Details

Title Does Mediterranean Diet Modify Phenoconversion in Huntington's Disease (HD) ?

Topic Movement Disorders

Presentation(s) P07 - (-)

Poster/Presentation
Number 211

Objective

Background BACKGROUND: We previously showed that in participants with CAG >37, higher caloric intake, but not body mass index (BMI), was associated with higher CAG (p=0.03) and increased 5-year probability of HD (p=0.013). Adherence to MeDi may delay onset of Alzheimer's and Parkinson's disease. Whether adherence to MeDi affects time to phenoconversion is unknown.

Design/Methods DESIGN/METHODS: At baseline, participants were 26-57 years and had not undergone genetic testing. A semi-quantitative food frequency questionnaire (FFQ) was administered [sim]30 months after baseline. We calculated daily gram intake for dairy, meat, fruit, vegetables, legumes, cereals, fish, monounsaturated and saturated fatty-acids, and alcohol, and constructed MeDi scores (0-9); higher scores indicate higher adherence. Demographics, medical history, BMI and Unified Huntington's Disease Rating Scale (UHDRS) were collected. We used Cox proportional hazards models to determine the association of MeDi and phenoconversion in participants with CAG >37.

Results RESULTS: Age, caloric intake, gender, education, and UHDRS motor scores did not differ when compared among MeDi tertiles (0-3, 4-5, 6-9). The highest BMI was associated with lowest adherence to MeDi. Among 211 premanifest individuals who completed the FFQ, 31 phenoconverted during follow up. In a model adjusted for age, CAG, and caloric intake, MeDi was not associated with phenoconversion (p for trend=0.13 for tertile of MeDi, and p=0.22 for continuous MeDi). When individual diet components of MeDi were analyzed, high dairy consumption (hazard ratio 2.36; 1.0-5.57; p=0.051) and higher caloric intake (p=0.04) were associated with risk of phenoconversion in an adjusted model.

Conclusions CONCLUSIONS: MeDi was not associated with phenoconversion, however higher consumption of dairy products had a two-fold increased risk. A larger study of premanifest individuals is necessary to explore the relationship to dairy products.

Authors/Disclosures
Karen S. Marder, MD, MPH, FAAN (Columbia University) PRESENTER	Dr. Marder has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Marder has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Marder has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Foundation . Dr. Marder has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CHDI. Dr. Marder has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC therapeutics. Dr. Marder has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer LTD. The institution of Dr. Marder has received research support from Vaccinex. The institution of Dr. Marder has received research support from Genentech. The institution of Dr. Marder has received research support from Triplet Therapeutics. The institution of Dr. Marder has received research support from Prilenia.
Yian Gu, PhD	The institution of Dr. Gu has received research support from NIH.
	No disclosure on file
Caroline M. Tanner, MD, PhD, FAAN (University of California San Francisco, Weill Institute for Neurosciences)	Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidera. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals/Cavion. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial . Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Genentech. The institution of Dr. Tanner has received research support from Gateway LLC. The institution of Dr. Tanner has received research support from Roche\Genentech. The institution of Dr. Tanner has received research support from Michael J Fox Foundation . The institution of Dr. Tanner has received research support from National Institute of Health . The institution of Dr. Tanner has received research support from Department of Defense. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Faculty, CME presentation with Medscape /WebND.
Nikolaos Scarmeas, MD, FAAN (Aeginition Hospital - National and Kapodistrian University of Athens)	Dr. Scarmeas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Albert Einstein Collego of Medicine. The institution of Dr. Scarmeas has received research support from NovoNordisc. The institution of Dr. Scarmeas has received research support from European Union Horizon Projects. The institution of Dr. Scarmeas has received research support from Hellenic Foundation for Research & Innovation .
	No disclosure on file
Ira Shoulson, MD (University of Rochester)	Dr. Shoulson has received research support from Vaccinex.
Ludwig Kappos, MD, FAAN (RC2NB, University Hospital Basel)	Dr. Kappos has nothing to disclose.

��ɫ��

��ɫ��